Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale...( VANCOUVER Aug. 13 / Angiotech Pharmac...)

VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced that it has received approval to begin marketing the Quill(TM) SRS Polydioxanone (PDO), MONODERM(TM), Polypropylene and Nylon product lines in Brazil.

"We are very excited about the approval of the Quill SRS product lines in Brazil, one of the largest surgical markets in the world. Quill has been lauded in the U.S., Europe and Canada for the efficiency it brings to wound closure. Now, Brazilian patients and surgeons in plastics, orthopedics and gynecology can benefit from it as well," said Dr. William Hunter, President and CEO of Angiotech.

The Quill SRS product lines include two absorbable sutures - MONODERM and PDO, and two non-absorbable sutures - Polypropylene and Nylon, and are approved for sale in the U.S., Europe, and Canada.

About the Quill(TM) Self-Retaining System (SRS)

Quill SRS represents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill SRS distribute tension across the wound and eliminate the need for knots.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Ca
'/>"/>